NasdaqGS - Nasdaq Real Time Price USD

Tarsus Pharmaceuticals, Inc. (TARS)

Compare
32.81 -0.33 (-1.00%)
As of 9:30 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
42,561.00
17,447.00
25,816.00
57,027.00
--
--
Cost of Revenue
3,247.00
1,593.00
955.00
2,075.00
--
--
Gross Profit
39,314.00
15,854.00
24,861.00
54,952.00
--
--
Operating Expense
195,204.00
159,012.00
87,573.00
67,109.00
26,998.00
--
Operating Income
-155,890.00
-143,158.00
-62,712.00
-12,157.00
-26,998.00
--
Net Non Operating Interest Income Expense
7,516.00
6,991.00
1,300.00
36.00
188.00
--
Other Income Expense
169.00
274.00
-683.00
-1,651.00
--
-331.00
Pretax Income
-148,205.00
-135,893.00
-62,095.00
-13,772.00
-26,810.00
--
Tax Provision
50.00
--
-4.00
55.00
1.00
--
Net Income Common Stockholders
-148,205.00
-135,893.00
-62,091.00
-13,827.00
-26,811.00
--
Diluted NI Available to Com Stockholders
-148,205.00
-135,893.00
-62,091.00
-13,827.00
-26,811.00
--
Basic EPS
-4.75
--
-2.52
-0.67
-4.32
-1.98
Diluted EPS
-4.75
--
-2.52
-0.67
-4.32
-1.98
Basic Average Shares
31,522.93
--
24,619.70
20,554.09
6,207.37
2,362.77
Diluted Average Shares
31,522.93
--
24,619.70
20,554.09
6,207.37
2,362.77
Total Operating Income as Reported
-155,890.00
-143,158.00
-62,712.00
-12,157.00
-26,998.00
--
Total Expenses
198,451.00
160,605.00
88,528.00
69,184.00
26,998.00
--
Net Income from Continuing & Discontinued Operation
-148,205.00
-135,893.00
-62,091.00
-13,827.00
-26,811.00
--
Normalized Income
-147,877.00
-136,269.00
-61,322.05
-12,675.06
-26,811.00
--
Interest Income
11,161.00
10,337.00
3,499.00
36.00
188.00
--
Interest Expense
3,519.00
3,225.00
2,064.00
--
--
--
Net Interest Income
7,516.00
6,991.00
1,300.00
36.00
188.00
--
EBIT
-144,686.00
-132,668.00
-60,031.00
-13,772.00
-26,998.00
--
EBITDA
-143,643.00
-131,791.00
-59,706.00
-13,460.00
-26,902.00
--
Reconciled Cost of Revenue
3,247.00
1,593.00
955.00
2,075.00
--
--
Reconciled Depreciation
1,043.00
877.00
325.00
312.00
96.00
--
Net Income from Continuing Operation Net Minority Interest
-148,205.00
-135,893.00
-62,091.00
-13,827.00
-26,811.00
--
Total Unusual Items Excluding Goodwill
-328.00
376.00
-769.00
-1,578.00
--
--
Total Unusual Items
-328.00
376.00
-769.00
-1,578.00
--
--
Normalized EBITDA
-143,315.00
-132,167.00
-58,937.00
-11,882.00
-26,902.00
--
Tax Rate for Calcs
--
--
0.00
0.00
0.00
--
Tax Effect of Unusual Items
--
--
-0.05
-426.06
--
--
12/31/2019 - 10/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MLYS Mineralys Therapeutics, Inc.
12.39
-2.36%
 
OCS Oculis Holding AG
11.80
-0.42%
 
APGE Apogee Therapeutics, Inc.
42.23
-2.06%
 
RCKT Rocket Pharmaceuticals, Inc.
22.48
-1.68%
 
XNCR Xencor, Inc.
21.04
-1.27%
 
SLN Silence Therapeutics plc
19.72
-5.19%
 
KROS Keros Therapeutics, Inc.
48.89
-1.23%
 
VRCA Verrica Pharmaceuticals Inc.
8.56
0.00%
 
IMVT Immunovant, Inc.
26.47
-0.51%
 
TSBX Turnstone Biologics Corp.
2.8100
+0.36%